Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay

Journal of Immunological Methods

Volumn 403, Issue 1-2, 2014, Pages 52-61

  Schwickart, Martin ^a   Mehrzai, Freshta ^a   Pearson, Jennifer ^a   Shaghasi, Nabila ^a   Chavez, Carlos ^a   Schneider, Amy ^a   Wu, Spencer ^a   Roskos, Lorin ^a   Liang, Meina ^a  

^a MEDIMMUNE   (United States)

Author keywords

Cell based; Immunogenicity; Matrix interference; MEDI 575; Neutralizing antibody; PDGF

Indexed keywords

CELL-BASED; IMMUNOGENICITY; MATRIX INTERFERENCE; MEDI-575; NEUTRALIZING ANTIBODY; PDGF;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOASSAY; LIGANDS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PREDICTIVE VALUE OF TESTS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84893797682     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.11.018     Document Type: Article

References (20)

1. Food and Drug Administration DRAFT - Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins 2009, U.S. Department of Health and Human Services.
2. Food and Drug Administration DRAFT - Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products 2013, U.S. Department of Health and Human Services.
3. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
4. Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J. Biol. Chem. 2001, 276:27406-27414.
5. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1-18.
6. Huang J.S., Huang S.S., Deuel T.F. Human platelet-derived growth factor: radioimmunoassay and discovery of a specific plasma-binding protein. J. Cell Biol. 1983, 97:383-388.
7. Klakamp S.L., Lu H., Tabrizi M., Funelas C., Roskos L.K., Coleman D. Application of analytical detection concepts to immunogenicity testing. Anal. Chem. 2007, 79:8176-8184.
8. Li X., Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev. 2003, 14:91-98.
9. McCutcheon K.M., Quarmby V., Song A. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. J. Immunol. Methods 2010, 358:35-45.
10. McDermott U., Ames R.Y., Iafrate A.J., Maheswaran S., Stubbs H., Greninger P., McCutcheon K., Milano R., Tam A., Lee D.Y., Lucien L., Brannigan B.W., Ulkus L.E., Ma X.J., Erlander M.G., Haber D.A., Sharma S.V., Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009, 69:3937-3946.
11. Pasanisi P., Venturelli E., Morelli D., Fontana L., Secreto G., Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1719-1722.
12. Rahbari N.N., Schmidt T., Falk C.S., Hinz U., Herber M., Bork U., Buchler M.W., Weitz J., Koch M. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011, 11:286.
13. Rodriguez-Gonzalez, R., Blanco, M., Rodriguez-Yanez, M., Moldes, O., Castillo, J., Sobrino, T. Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator. Atherosclerosis 226, 2013, 165-71.
14. Rykala J., Przybylowska K., Majsterek I., Pasz-Walczak G., Sygut A., Dziki A., Kruk-Jeromin J. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol. Oncol. Res. 2011, 17:809-817.
15. Seifert R.A., van Koppen A., Bowen-Pope D.F. PDGF-AB requires PDGF receptor alpha-subunits for high-affinity, but not for low-affinity, binding and signal transduction. J. Biol. Chem. 1993, 268:4473-4480.
16. Thomson S., Petti F., Sujka-Kwok I., Epstein D., Haley J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 2008, 25:843-854.
17. Tiesman J., Hart C.E. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. J. Biol. Chem. 1993, 268:9621-9628.
18. Vugmeyster Y., Xu X., Theil F.P., Khawli L.A., Leach M.W. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J. Biol. Chem. 2012, 3:73-92.
19. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 2003, 278:1-17.
20. White J.T., Martell L.A., Van Tuyl A., Boyer R., Warness L., Taniguchi G.T., Foehr E. Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). AAPS J. 2008, 10:363-372.